Mazdutide
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
Innovent · Phase 2 · Completed · Enrollment 179
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- 10 mg Mazdutide, one timepoint
- 16 mg Mazdutide, one timepoint
- Placebo, one timepoint
- 3/6 mg Mazdutide, one timepoint
- 10 mg Mazdutide: week 32 96.1%
- 16 mg Mazdutide: week 32 92.23%
- Placebo: week 32 23.97%
- 3/6 mg Mazdutide: week 32 67.64%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.